Two Patients Planning Pregnancy, Two Very Different Clocks on Their DMT
Two women in the same clinic, both hoping to conceive inside six months, both on a drug that complicates it — in opposite directions. One drug can plausibly continue through pregnancy. The other has to be actively driven out of the body, and nobody has started the clock.
R.V. is 30, teaches high-school chemistry, and spent the first two years of her MS having four relapses. Natalizumab, started after the fourth, has held it completely: three years now with no relapse and no new lesion, long enough that she and her partner have begun planning the family they had put aside while her disease was still unpredictable. They hope to start trying within six months. She is JC-virus seronegative, which removes the PML consideration that dominates most natalizumab conversations and leaves this one unusually clean: the drug is not a long-term liability for her, only a pregnancy-timing problem.
The usual teratogenicity conversation is not the one her case turns on. Natalizumab crosses the placenta increasingly as pregnancy advances, but it has not shown the kind of structural signal that would argue for stopping on fetal grounds alone. The risk sits on her side of the pregnancy. Portaccio and colleagues, working from the Italian registry, found post-withdrawal relapse risk concentrated specifically in women whose pre-treatment disease was highly active, and Roos and colleagues' MSBase analysis found the same pattern outside pregnancy entirely — which is a precise description of someone who had four relapses in two years before this drug. What returns after natalizumab stops can exceed the baseline it was started from, and for R.V. that is not a statistical abstraction: her fourth relapse was an optic neuritis two weeks before her wedding, and she brought the pregnancy conversation to this visit rather than letting it come up incidentally. Three years of nothing happening is not, for her, evidence that nothing would happen again. It is evidence of what the drug is doing.
R.V., planning conception on natalizumab
I'd continue natalizumab through conception and into pregnancy, with a planned dose interval extension in the third trimester rather than an outright stop. Her disease history — four relapses in two years before this drug — is exactly the profile where the pregnancy cohorts point toward continuing: Portaccio and colleagues, working from the Italian MS registry, found relapse risk after natalizumab withdrawal for pregnancy concentrated specifically in women with high pre-treatment activity, and Roos and colleagues' MSBase analysis of cessation found the same pattern outside pregnancy. The alternative isn't a neutral pause. It's a documented rebound risk during a window that's hard to treat.
If her disease had been mild before natalizumab, I'd be having a much more conventional conversation about a pregnancy-compatible switch — it's specifically how badly her disease behaved before this drug that changes my calculation here.
I want to name directly what continuing through pregnancy actually costs. Natalizumab is an IgG4 antibody, so placental transfer rises through the second and third trimesters, and Haghikia and colleagues described the consequence in a neonatal series: mild anemia and thrombocytopenia in babies exposed in the third trimester, mostly transient, but real enough that the delivery team needs to be expecting it rather than discovering it.
I'm not arguing to stop the drug outright — the rebound risk you're describing is real and I take it seriously. I'm saying 'continue' has its own real, if manageable, cost that belongs explicitly in this conversation rather than being treated as the risk-free option once we've ruled out stopping.
Agreed: continue natalizumab through conception and into pregnancy, with interval extension planned for the third trimester and the neonatology team briefed in advance to monitor for transient neonatal hematologic changes at delivery. Her own preference, once the tradeoff was laid out plainly, was to prioritize disease control given how her MS behaved before this drug.
Not agreed: exactly how late into pregnancy the interval-extension should begin, since no fixed protocol exists and the group's own literature review found real practice variation on this specific timing question. Left as a decision to revisit with her obstetric team as the pregnancy actually progresses, not settled today.
C.H. manages a restaurant, is 33, and has been stable on teriflunomide for two years — one relapse in that span, no new lesions in the last twelve months. She and her spouse are aiming at roughly the same six-month window as R.V., one floor down in the same clinic.
Her problem is not whether the drug is safe in pregnancy. It plainly is not; teriflunomide is a known teratogen and there is no version of continuing through conception available to her. Her problem is how long it takes to stop being one, and that turns out to be the part nobody has costed.
Elimination is unusually slow and unusually variable, sometimes running past two years, because enterohepatic recirculation keeps returning the drug to the circulation rather than letting it clear on the schedule an oral medication normally would. The accelerated elimination procedure exists to interrupt that, and the teriflunomide label specifies it precisely: cholestyramine over eleven days, then two plasma concentrations drawn at least fourteen days apart, both required to fall below 0.02 mg/L. The confirmation is not a formality attached to the end of the course. It is the only thing that distinguishes a completed procedure from a cleared patient — and the two are separated by enough variability that assuming the first implies the second is precisely the error the confirmation step exists to catch.
Nobody has drawn a level. That is the actual clinical problem hiding inside a conversation that sounds like it needs a start date, because six months from now is only six months of clearance if the clearance started six months ago. The slow season she and her spouse picked to begin trying is closer, measured in this drug's kinetics, than either of them has reason to think.
C.H., planning conception on teriflunomide
I'd start the accelerated elimination procedure with cholestyramine now, today, rather than waiting closer to her planned conception window. Teriflunomide's elimination half-life is long and variable enough that 'six months from now' isn't the same as 'six months of actual washout' unless the washout itself starts well before that.
If she weren't planning conception for another two years, I wouldn't be pushing to start this today — the urgency here is specifically about how close her stated timeline already is to how long this process reliably takes.
I agree with starting the washout, and I want to add the piece that often gets treated as a formality: two plasma levels, two weeks apart, both below the defined safety threshold, before conception is attempted — not just completing the cholestyramine course and assuming it worked.
I don't think the group should treat 'started the washout' and 'confirmed clear' as interchangeable, which is a real risk if her plasma levels aren't actually drawn and reviewed before she and her spouse start trying — the confirmation step is not optional.
Agreed: cholestyramine washout started today, with two plasma teriflunomide levels drawn fourteen days apart before she and her spouse begin actively trying to conceive. Her MS will be monitored closely during the washout window given her recent relapse history, since the group has not yet decided what bridges her disease control during the gap before a pregnancy-compatible option, if needed, is in place.
Not agreed: whether a pregnancy-compatible DMT should be started during the washout-to-conception interval given her one relapse in the past two years, or whether that interval is short enough to monitor without treatment. Left open, with a plan to reassess once her confirmatory plasma levels return and an actual timeline to conception becomes clearer.